PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Although the activation of the AMPK-PGC-1α/Nrf2 pathway has emerged as a promising strategy for treating metabolic disorder-related diseases, including NAFLD, the effect of AKG in this pathway remains unknown.